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ABSTRACT
Purpose: To propose guidelines for the
management of patients with wet age-related
macular degeneration (wAMD), taking into
account the results of large multicenter studies
and clinical experience of retina experts.
Method: A team of retina experts developed a
consensus paper after three consecutive
meetings. The group was focused on
guidelines to help clinical decision-making
around the definition of successful treatment
and the definition of non-response to therapy.
Results: Parameters suggestive of a successful
response to treatments included: any gain in
best corrected visual acuity (BCVA) or vision
loss that is less than 5–10 Early Treatment
Diabetic Retinopathy Study (ETDRS) letters,
reduction of central retinal thickness, partial
or complete absorption of subretinal fluid (SRF),
reduction of intraretinal fluid, reduction of
pigment epithelial detachment or restoration
of the anatomy of outer retinal layers.
Non-response to current treatment was
considered in the case of loss of BCVA greater
than 10 ETDRS letters, increased retinal edema
or increase of SRF as evidenced by optical
coherence tomography or new bleeding in
biomicroscopy.
Conclusion: The introduction of anti-VEGF
agents revolutionized the treatment of wAMD.
Given the complexity of the disease, the
emerging new agents and the difference of
cases recruited in clinical trials compared to
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those appearing in every-day practice, it is
essential to individualize treatment options
taking into account the results of clinical trials.
Keywords: Age-related macular degeneration;
Consensus; Ophthalmology; Recommendations
INTRODUCTION
According to recent epidemiological data, 2.3%
of the population aged over 65 years in Europe
is suffering from neovascular (wet) age-related
macular degeneration (wAMD), with the disease
posing a significant public health problem
[1–3]. wAMD is diagnosed less often than dry
AMD, yet it accounts for 90% of severe vision
loss cases [1, 2].
During the past decade, new targeted
treatments against vascular endothelial growth
factor (anti-VEGFagents)havebeen introduced in
themanagement ofwAMDpatients changing the
visual prognosis in these patients [4]. A large
benefit in vision of patients treated with
ranibizumab was initially highlighted in large
multicenter trials, followed by the use of
bevacizumab and recently aflibercept [5–9].
Moreover, diagnostic technologies, and
especially optical coherence tomography (OCT)
have revolutionized the AMD diagnosis and
treatment algorithm [10]. However, despite
positive developments in disease management,
there are no commonly accepted therapeutic
response evaluation criteria. This is particularly
truewhen the discussion is not limited to patients
that are selected based on criteria similar to those
in large clinical trials, but when referring to the
individual patient, treated by anophthalmologist
in everyday clinical practice. In addition, there is
ongoing research for parameters predictive or
suggestive of no response to anti-VEGF therapy
since the characteristics of patients not
responding to treatment are not clearly defined.
Thus, deriving the maximum possible benefit for
each individual patient in the clinic becomes
more difficult.
The purpose of this article is to present
guidelines, compiled by a panel of specialized
ophthalmologists in the area of wAMD, and
propose commonly accepted therapeutic
response criteria and define treatment
discontinuation criteria for patients suffering
from wAMD treated with anti-VEGF agents.
METHODS
A team of Greek retina experts developed a
consensus paper after three consecutive
meetings. The expert panel reviewed the
peer-reviewed literature with the goal to
establish practical guidelines for the practicing
ophthalmologist. The group was focused on
guidelines to help clinical decision-making
around the definition of successful treatment
and the definition of non-response to therapy.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
INITIAL EVALUATION
Prior to treatment initiation, compliance with
the examination algorithm depicted in Fig. 1 is
suggested. It is important to establish an initial
diagnosis of wAMD before initiating treatment.
Naturally, signs of the disease include central
vision loss and metamorphopsia. Family history
of AMD as well as social habits like smoking is
important and should be recorded.
Concomitant disease, e.g., arterial
hypertension or diabetes mellitus should also
be recorded. At baseline, it is expected that best
corrected visual acuity (BCVA), dilated fundus
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examination, fluorescein angiography and
optical coherence tomography (OCT) should
be performed in order to confirm the diagnosis
of wAMD and establish baseline criteria for
evaluation of the treatment effect. Indocyanine
green angiography (ICG) is not performed
routinely. It is, however, indicated in those
patients where choroidal neovascularization
(CNV) due to other etiologies is suspected and
needs to be ruled out. The differential diagnosis
from chronic central serous chorioretinopathy,
retinal angiomatous proliferation (RAP) and
polypoidal choroidal vasculopathy (PCV) is
important also due to their different prognosis
and treatment strategy [11–14].
After initiation of treatment, three monthly
injections are advised. The frequency of
follow-up and criteria for treatment
administration thereafter depends on the
treatment scheme that is adopted (monthly,
pro re nata or treat and extend strategy, etc.).
Follow-up is based on the evaluation of
functional and morphological parameters to
assess disease activity.
Various dosage schemes have been offered to
patients given the real-life limitations that a
costly and intensive treatment scheme of fixed
monthly injections can encounter in practice.
Results from the use of less intensive dosing
schemes of ranibizumab, bevacizumab and




AURA (NCT01447043), CATT (NCT00593450),
IVAN (ISRCTN92166560) and CLEAR-IT2
(NCT00320788) have been generally variable
and inferior to monthly dosing; however, the
Fig. 1 Patient management prior to treatment initiation.
AMD age-related macular degeneration, CNV choroidal
neovascularization, FA ﬂuorescein angiography, OCT optical
coherence tomography, PCV polypoidal choroidal
vasculopathy, BCVA best-corrected visual acuity
measurement, ICGA indocyanine green angiography
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pro re nata dosing regimen is commonly used in
practice [7–9, 15–19].
FUNCTIONAL PARAMETERS
Visual acuity constitutes the main functional
parameter for quantitative evaluation of
functional response in the treatment of wAMD
and the main criterion that influences clinical
decision-making. Tests to assess function are of
primary importance, since they try to measure
the loss that the patient experiences in life.
Additional psychophysical methods such as
contrast sensitivity and microperimetry may
be used as ancillary methods, but are not
usually part of the clinic routine (Table 1).
Near visual acuity is also important.
Standardized testing of BCVA with Early
Treatment Diabetic Retinopathy Study (ETDRS)
charts helps reduce variability that is associated
with the measurement of this parameter.





Changes in visual symptoms and in patient’s
subjective complaints regarding vision should
be recorded. Any level of vision improvement in
a wAMD patient may be defined in effect as a
positive outcome. Vision loss that does not
exceed 5–10 EDRTS letters (1–2 Snellen lines)
can also be considered an outcome that is better
compared to the natural history of the disease.
Left untreated, the CNV lesion will grow to
involve the fovea and cause more profound
vision loss.
In reality, the minimum visual benefit for
the patient would be to sustain vision loss that
is less compared to that if left untreated,
according to the natural history of the disease.
The natural history of the disease has been
documented in several studies and also
supported by findings in untreated eyes in the
Macula Photocoagulation Study
(Clinicaltrials.gov identifier, NCT00000158)
[20–23]. The results from the large scale,
carefully conducted, multicenter, randomized
controlled clinical trials can also be used to
reveal the natural history of the disease, where
comparisons are made against the placebo arm.
Measurement variability and uncertainty exists
in trials and clinical practice as well. Results
from the MARINA study (Clinicaltrials.gov
identifier, NCT00056836) indicated a 2-year
loss of 14.9 ETDRS letters in the sham
injection group [24]. In the ANCHOR study
(Clinicaltrials.gov identifier, NCT00061594), a
Table 1 Functional parameters to characterize treatment response
Functional parameters Method of measurement Comments
Best-corrected visual acuity Snellen optotype Most popular. Widely used in clinical practice
ETDRS optotype More precise examination. Optotype of choice in
multicenter clinical studies
Contrast sensitivity Contrast sensitivity optotypes
(e.g., Pelli–Robson)
Ancillary examination as per treating physician
clinical judgment
Microperimetry Fundus microperimeter Ancillary examination as per treating physician
clinical judgment
ETDRS Early Treatment Diabetic Retinopathy Study
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loss of 9.5 letters with verterporfin at 12 months
was reported [6]. The PIER study found a mean
loss of 16.3 ETDRS letters in 1 year [9]. A recent
meta-analysis of the literature also supports a
mean decrease of 4 lines in visual acuity at
24 months [25]. It is also recognized that the
visual gain is dependent on starting visual
acuity and there is also a ceiling effect when
exploring results in patients with good starting
BCVA. There is also a floor effect in cases of low
visual acuity, highlighting the limitations in
looking only at the change in the number of
letters, without taking into consideration the
starting BCVA. However, in order to provide a
recommendation for use in clinical practice, the
panel ascribed any level of visual gain or a loss
that is less than 10 ETDRS letters as a response
that is better than the natural history of the
disease.
ANATOMIC PARAMETERS
Morphological evidence of the disease status is
essential, since it often precedes functional
deficit and it can alert the physician as to the
disease activity.
In general, structure and function do not
correlate very well and are supposed to provide
different information on the disease status [26].
This disconnect between structure and function
has long been recognized and attempts have
been made in order to propose morphological
parameters that could predict the functional
outcome [27]. In fact, morphological signs of
disease activity on OCT, are given primary
importance since they correspond to early
signs of recurrence, usually observed before
BCVA loss [28]. Moreover, it has been
recognized that anatomic parameters at
baseline may also carry prognostic
information, with foveal intraretinal fluid
being associated with worse visual outcome
and subretinal fluid interestingly, being
associated with better visual outcome [29, 30].
Table 2 depicts the main anatomic
parameters taken into consideration. Their
evaluation is performed based on spectral
domain-OCT scans.
Techniques, such as angiography and
autofluorescence are particularly important in
special circumstances (Table 3). Angiography is
also useful in case of recurrence. Otherwise,
OCT has emerged as the most useful tool to
provide evidence of morphological response to
treatment or signs of recurrence. Parameters
that are important to monitor on OCT are
central retina thickness (CRT), presence of
subretinal fluid (SRF) or intraretinal fluid, the
anatomy of the outer retina layers and the
presence and extent of pigment epithelial
detachment (PED). Most of these parameters
can quantitatively measure the efficacy of the
treatment regimen.
THERAPEUTIC RESPONSE
DEFINITION BASED ON ANATOMIC
PARAMETERS
Response to treatment is evaluated based on
anatomic and functional criteria. Anatomic
criteria can provide qualitative and
quantitative information. Based on anatomic






Anatomy of the outer retinal layers
Pigment epithelium detachment
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parameters, a positive outcome of a therapeutic
intervention is defined as:
• Reduction in CRT compared to baseline. CRT
ranging between 250–350 lm is generally
considered satisfactory.
• Partial or complete resolution of subretinal
fluid.
• Reduction in subretinal fluid versus baseline.
• Reduction in PED extent and height.
• Restoration of the outer retinal layers
anatomy.
Observations
• Lack of relapses constitutes an additional
efficacy criterion. The time free of disease
activity should be taken into account when
evaluating the effect of treatment.
• Re-treatment criteria include
non-stabilization and fluctuation of visual
acuity (continuing improvement or gradual
deterioration), as well as anatomic
deterioration (e.g., retinal thickness
increase by 100 lm, PED or increase in SRF).
• In the case of bilateral disease, concomitant
and independent treatment administration




It is a recognized fact that not all patients
respond to treatment. Nine percent and 10% of
patients treated in the MARINA and ANCHOR
trials with monthly ranibizumab experienced a
loss in BCVA of more than 15 letters at 2 years
[24]. The definition of non-response to
treatment is based on the findings described
below from functional and anatomic
parameters. However, it is understood that
ongoing visual acuity loss may in fact result
from the development of scarring or
geographic atrophy in the center of the fovea,
and not only from non-response to the
administered anti-VEGF treatment [32].
Therefore, anatomic signs of ongoing wAMD
activity should in fact be carefully taken into
account to support non-response to anti-VEGF
therapy.
Functional Parameters
• Vision loss of more than 10 ETDRS letters (or
2 Snellen lines).




Routine examination during baseline visit
Examination of choice at the monthly follow-up
Fluorescein angiography
(FA)
Routine examination during baseline visit
Lesion size and leak extent/intensity monitoring
Indocyanine green
angiography
Not a routine examination during baseline visit
Complementary to FA in order to collect information in case of a diagnostic problem or
suspicion of latent or other lesion (such as PCV)
Autoﬂuorescence (AF) Useful for the assessment and evaluation of macular atrophy. Ancillary examination as per
treating physician clinical judgment
PCV polypoidal choroidal vasculopathy
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Anatomic Parameters
• Edema increase (CRT increase[100 lm).
• Increase in SRF.
• New hemorrhages in dilated fundus exam.
If there is no functional and/or anatomic
improvement (i.e., stable low or declining
vision and/or persisting fluid in the OCT) after
a series of at least three monthly treatment
repetitions, non-response to treatment is being
suspected. Compliance with the monthly
injection scheme is important to evaluate
response. In fact the problem of
undertreatment is very important and may
underlie the lack of observed response to
anti-VEGF therapy. Therefore, it should be
emphasized that the decision of non-response
to treatment may only be made when the strict
protocol of 4-weekly treatment intervals has
been followed.
In this case, a re-evaluation should be
performed using FA/ICGA or any other
method considered appropriate by the treating
physician to rule out other entities.
If the diagnosis of choroidal
neovascularization due to wAMD is confirmed
then:
• The treatment should be continued on a
monthly basis, for up to a total of 6 months.
Findings from subgroup analysis from
patients enrolled in the MARINA and
ANCHOR pivotal trials support a net
benefit in vision with continued monthly
injections [33]. It has also been suggested
that the change in visual acuity with
ranibizumab is associated with lesion
characteristics [24].
If a benefit is not observed afterwards, the
treating physician may choose to switch to a
different drug. The evidence to support a
change in the administered anti-VEGF agent
mainly comes from retrospective case series,
without a control group [34–39]. However,
analysis of data from the CATT showed in fact
that eyes that are considered non-responders,
may in fact benefit from continued treatments,
with an increase in vision and a better
morphological outcome, without switching to
another agent [40]. Future studies will provide
more evidence to guide clinical practice in this
regard.
It has also been proposed that some patients
may develop tachyphylaxis after repeated doses
of the drug [41]. If this is the case, patients
usually respond well initially, but gradually
become resistant to further injections. A
change in the drug of choice may be indicated
in these patients [42, 43].
Chronicity of the disease that has already
caused irreversible damage might also be
suspected. Presence of permanent structural
damage or extensive fibrotic lesion or central
atrophy would not allow the vision to recover.
Hence, switching to a different drug in these
patients is less likely to provide improvement in
vision. Presence of polypoidal choroidal
vasculopathy might also need combined
treatment with anti-angiogenic intravitreal
injections and photodynamic therapy. It has
also been suggested that some patients may
require more frequent dosing than others [44].
The algorithm in Fig. 2 shows patient
follow-up upon suspicion of non-response or




In the case of a patient that fulfills the
below-mentioned criteria, (s)he is
characterized as non-responder and may
discontinue anti-angiogenetic factor treatment:
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• Visual acuity decline at a level less than 1/20
in three sequential visits, due to wAMD.
• Lesion morphology deterioration, suggesting
ongoing activity, despite appropriate
treatment (e.g., progressive increase in the
size of the lesion confirmed with fluorescein
angiography, features on OCT suggesting
disease activity or new hemorrhages or
exudates (not related to vascular disease),




IN THE OTHER EYE
Patients that already sustained profound central
vision loss in the other eye should probably be
treated individually, having a lower threshold
for administering treatment. These patients are
already at a higher risk of developing wAMD in
the fellow eye, therefore close monitoring and
timely treatment is indicated [45–47].
CONCLUSION
The purpose of this paper is to provide a
consensus document concerning functional
and anatomic criteria used in the evaluation of
anti-VEGF treatment response and treatment
discontinuation, as a guide in everyday clinical
practice regarding the optimal treatment of
wAMD. It has already been a decade since the
FDA and EMA approval of ranibizumab in the
United States and Europe for all wAMD lesion
types and recently, a second drug, aflibercept,
has been approved [5, 8]. It is true that
intravitreal anti-angiogenetic treatment has
changed the prognosis for patients with
wAMD [48, 49]. Therefore, it is important to
determine qualitative and quantitative criteria
that can characterize a patient’s response to
treatment [31, 50, 51].
Real-world studies have generally been
associated with inferior outcomes, compared
to those reported in the pivotal trials [52]. It is
recognized that the clinical situations and
variations that arise in clinical practice are not
identical to those met in the well-designed
clinical trials that led to the introduction of
the drugs. Moreover, patients are generally
harder to adhere to the intensive monitoring
and treatment scheme in clinical practice.
Importantly, early diagnosis and initiation of
treatment are essential for a successful outcome.
Compliance with treatment is another crucial
factor. It is currently believed that initiation of
anti-VEGF therapy should not be delayed to
ensure that anatomical signs of activity are
short lived and that chronic changes have not
already damaged the photoreceptor layer [28].
Fig. 2 Management algorithm in patients when there is
suspicion of non-response to anti-VEGF injection. AMD
age-related macular degeneration, FA ﬂuorescein
angiography, ICGA indocyanine green angiography
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Success has also been variable with different
treatment schemes to ensure the same outcome
can be achieved with less-than-monthly dosing
used in the pivotal ranibizumab trials. Efforts
oriented to improve patient compliance with
treatment schedule are advocated.
Additionally, knowledge around genetic
factors that appear to be important factors
controlling response to anti-VEGF treatment is
also emerging. Interestingly, low-risk
complement factor H phenotypes may in fact
predict a favorable response compared to the
high-risk group [53]. It remains, however,
unknown how this increasing knowledge can
translate in clinical practice and whether it will
change our treatment approach.
Advances in imaging modalities have
definitely revolutionized diagnosis and
follow-up of wAMD. OCT has emerged as an
essential tool in the care of patients with wAMD
nowadays. Fundus autofluorescence imaging
and indocyanine green angiography provide
useful information in selected cases. It remains
to be seen how advances in OCT angiography
will change the approach to diagnosis and
treatment in those patients.
Morphological evidence of disease activity is
crucial, since it provides objective information
and can earlier detect activity or recurrence.
Fibrosis resulting in permanent disruption of
tissue architecture and loss of the outer layers
cause irreversible loss of central vision.
Therefore, treatment of the lesion before
permanent damage has occurred is essential.
Finally, progression of atrophy should be
carefully observed during prolonged
treatment, since it represents an important
factor in determining visual outcome [54].
Given the chronic nature of the disease, future
studies may further highlight factors that are
important for the long-term visual prognosis of
the individual wAMD patient.
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